FDA grants Breakthrough Therapy Designation to Hemab Therapeutics’ sutacimig for Glanzmann thrombasthenia. Discover what this means for bleeding disorder treatment.
Akeso and INOVIO test cadonilimab plus INO-5412 in the INSIGhT glioblastoma trial. Explore what this immunotherapy strategy could mean for GBM research.
Find out how zenocutuzumab treatment beyond progression could change care for NRG1 fusion-positive lung cancer and what clinicians should watch next.
Twist Bioscience licenses Invenra’s bispecific antibody platform. Find out how this reshapes biologics discovery infrastructure and industry dynamics.
Janux Therapeutics begins first human study of JANX011. Find out how CD19 immune reset could change autoimmune treatment strategies.
WuXi Biologics and Sinorda Biomedicine have entered into a strategic collaboration to advance the development and clinical manufacturing of SND006, a novel bispecific antibody targeting inflammatory bowel disease and other autoimmune conditions. The agreement will see Sinorda Biomedicine utilize WuXi Biologics’ CRDMO capabilities to support preclinical development, IND-enabling activities, and global clinical supply for SND006,
Find out why Boehringer is betting big on Simcere’s bispecific SIM0709 to challenge the IBD treatment ceiling.
AbbVie’s Phase 3 epcoritamab data raise critical questions about survival endpoints and bispecific antibodies in relapsed lymphoma. Read the full analysis.
Genmab’s epcoritamab improved PFS in a Phase 3 DLBCL trial. Find out how this could reshape bispecific monotherapy in aggressive B-cell lymphoma care.
Celltrion is going all-in on oncology biologics with ADCs, msAbs, and U.S. biomanufacturing scale-up. Find out what this shift means for global competition.